Stockscreener 앱 받기
49.62
0.82%
-0.435
전일 마감가:
$50.05
열려 있는:
$48.77
하루 거래량:
2.06M
Relative Volume:
0.67
시가총액:
$121.80B
수익:
$43.23B
순이익/손실:
$6.79B
주가수익비율:
12.39
EPS:
4.0051
순현금흐름:
$9.17B
1주 성능:
-2.78%
1개월 성능:
-2.48%
6개월 성능:
-10.46%
1년 성능:
-6.25%
1일 변동 폭
$48.67
$49.80
1주일 범위
$48.67
$51.63
52주 변동 폭
$44.62
$60.12
사노피 ADR Stock (SNY) Company Profile
SNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
49.62 | 121.92B | 43.23B | 6.79B | 9.17B | 4.0051 |
|
LLY
Lilly Eli Co
|
889.37 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
187.06 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
215.31 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
124.80 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.30 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
사노피 ADR Stock (SNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-08-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-03-21 | 개시 | Goldman | Neutral |
| 2025-01-30 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-07-26 | 재확인 | Argus | Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-10-30 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-09-06 | 업그레이드 | Berenberg | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-28 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 재개 | Morgan Stanley | Overweight |
| 2022-08-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-08-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-09-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 개시 | Deutsche Bank | Sell |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-03-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-03-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-02-11 | 개시 | SVB Leerink | Mkt Perform |
| 2020-01-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 개시 | Bernstein | Outperform |
| 2019-08-14 | 업그레이드 | UBS | Neutral → Buy |
| 2018-12-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-11-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-03-23 | 업그레이드 | Liberum | Hold → Buy |
| 2018-01-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2017-08-30 | 업그레이드 | HSBC Securities | Reduce → Hold |
모두보기
사노피 ADR 주식(SNY)의 최신 뉴스
Pulmonary Emphysema Market Set to Expand by 2034 with Rising COPD Prevalence and Therapeutic Innovation | DelveInsight - GlobeNewswire Inc.
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness - Sahm
UPDATE - GlobeNewswire Inc.
Sanofi ADR earnings beat by $0.72, revenue fell short of estimates - Investing.com Nigeria
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark - Sahm
Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy - Sahm
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease - Sahm
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times - Sahm
Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study - The Globe and Mail
Sanofi (SNYNF) Gets a Buy from J.P. Morgan - The Globe and Mail
SanofiAmerican Depositary Shares (NQ: SNY - FinancialContent
UBS Reaffirms Their Buy Rating on Sanofi (SNYNF) - The Globe and Mail
Leerink Partners Sticks to Its Buy Rating for Sanofi (SNYNF) - The Globe and Mail
BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals
Sanofi Expands Insulin Savings Program To Cover All US Patients - Sahm
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Sahm
Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability - Sahm
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit - Sahm
Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS® - Ariva
Leerink Partners Sticks to Their Buy Rating for Sanofi (SNY) - The Globe and Mail
What's Going On With Nektar Therapeutics Stock On Thursday? - Sahm
Why Is Sanofi Stock Falling Thursday? - Sahm
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Sahm
New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week - Ariva
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
사노피 ADR (SNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
0.07%
자본화:
|
볼륨(24시간):